Have a feature idea you'd love to see implemented? Let us know!

DNLI Denali Therapeutics Inc

Price (delayed)

$23.95

Market cap

$3.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.77

Enterprise value

$3.41B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
The EPS has plunged by 198% YoY but it has increased by 3.1% from the previous quarter
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ
Denali Therapeutics's gross profit has shrunk by 100% QoQ and by 100% YoY
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
143.92M
Market cap
$3.45B
Enterprise value
$3.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$427.46M
EBITDA
-$418.91M
Free cash flow
-$375.69M
Per share
EPS
-$2.77
Free cash flow per share
-$2.22
Book value per share
$9.21
Revenue per share
$0
TBVPS
$8.58
Balance sheet
Total assets
$1.45B
Total liabilities
$135.52M
Debt
$52.52M
Equity
$1.32B
Working capital
$781.75M
Liquidity
Debt to equity
0.04
Current ratio
9.98
Quick ratio
9.61
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30%
Return on equity
-32.9%
Return on invested capital
-32.8%
Return on capital employed
-31.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
0.25%
1 week
-4.81%
1 month
-11.98%
1 year
27.6%
YTD
11.6%
QTD
-17.78%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$490.07M
Net income
-$427.49M
Gross margin
N/A
Net margin
N/A
DNLI's operating income has dropped by 189% year-on-year
Denali Therapeutics's gross profit has shrunk by 100% QoQ and by 100% YoY
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 198% YoY but it has increased by 3.1% from the previous quarter
DNLI's price to book (P/B) is 41% less than its 5-year quarterly average of 4.4
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ
DNLI's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Denali Therapeutics business performance
The return on equity has dropped by 186% year-on-year but it has increased by 2.1% since the previous quarter
The return on invested capital has dropped by 176% year-on-year but it has increased by 3% since the previous quarter
The return on assets has increased by 2.3% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
The current ratio has contracted by 38% YoY and by 20% from the previous quarter
The quick ratio has declined by 38% year-on-year and by 20% since the previous quarter
Denali Therapeutics's debt is 96% less than its equity
DNLI's debt to equity is down by 20% year-on-year
Denali Therapeutics's equity has increased by 18% YoY but it has decreased by 4.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.